Valuation Trading Multiples & Precedent Transactions: Small-Molecule Pharmaceutical Manufacturing Companies
Valuation benchmarks for Small-Molecule Pharmaceutical Manufacturing Companies. Access public trading comps, EV/EBITDA acquisition multiples, and private market data for pitch books and valuation analysis.
1.1 - Small-Molecule Pharmaceutical Manufacturing Companies Market Context & Valuation Drivers
Companies in this group research, manufacture, and commercialize small-molecule therapeutics across branded specialty, generics, and sterile injectables. Many operate integrated platforms spanning formulation, cGMP production, and multi-channel distribution to hospitals and pharmacies. They are grouped as public trading comparables given similar regulatory exposure, product mix, and revenue models anchored in prescription drug sales, tender contracts, and OTC offerings, enabling consistent valuation benchmarks.
Typical capabilities include discovery and development of chemical entities, formulation and scale-up, regulatory submissions, and cGMP manufacturing for oral solids, liquids, and injectables. Companies offer sterile compounding, specialty injectables, anesthesia and critical-care drugs, oncology and immuno-inflammatory small molecules, ophthalmic and dermatology products, and OTC formulations. Many manage hospital tendering, pharmacovigilance, and global distribution, while pursuing licensing, co-development, and lifecycle management to extend indications and defend margins.
Primary customers include hospitals and health systems, retail and specialty pharmacies, government procurement agencies, and clinical practices. Valuation drivers typically include revenue growth by therapeutic area, gross margin mix between branded and generic portfolios, approval cadence and pipeline productivity, tender win rates and market share in key indications, and operating leverage from manufacturing scale and distribution reach, which impact cash generation and return on invested capital.
2. Valuation Analysis: Public Trading Comps & Multiples for Small-Molecule Pharmaceutical Manufacturing Companies companies
2.1 - Public Peer Groups & Median Valuation Multiples for Small-Molecule Pharmaceutical Manufacturing Companies sector
Comparable group 1: Small-Molecule Pharmaceutical Manufacturing Companies
Fagron
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of pharmaceutical compounding solutions and personalized medicine services, utilizing advanced technology to meet the specific needs of healthcare providers and patients globally.
- Key Products:
- Sterile compounding: Production of individual sterile medications with rigorous quality control
- Custom formulations: Unique pharmaceutical preparations tailored to meet specific patient needs
- Fagron TrichoConcept: Multifunctional compounding vehicles for alopecia treatment with patented TrichoTech technology
- FagronLab Equipment: Advanced compounding tools and systems for pharmacies
- Fagron Formulary: Comprehensive range of customizable formulas for pharmacists and prescribers.
Bausch Health
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of pharmaceutical products in the fields of gastroenterology, hepatology, neurology, dermatology, and other healthcare sectors, focusing on enhancing health outcomes through diversified product offerings.
- Key Products:
- Eye Health Products: Comprehensive eye care solutions through Bausch + Lomb
- Gastroenterology Medications: Treatments for digestive health issues
- Neurology Devices: Solutions for neurological conditions
- Dermatology Products: Skincare solutions addressing various conditions
- Dental Products: Instruments and solutions for dental care.